ELVN logo

Enliven Therapeutics, Inc. (ELVN) Total Expenses

Annual Total Expenses:

$89.02M+$17.44M(+24.36%)
December 31, 2024

Summary

  • As of today, ELVN annual total expenses is $89.02 million, with the most recent change of +$17.44 million (+24.36%) on December 31, 2024.
  • During the last 3 years, ELVN annual total expenses has risen by +$64.28 million (+259.84%).
  • ELVN annual total expenses is now at all-time high.

Performance

ELVN Total Expenses Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherELVNincome statement metrics

Quarterly Total Expenses:

$20.15M-$5.19M(-20.47%)
September 30, 2025

Summary

  • As of today, ELVN quarterly total expenses is $20.15 million, with the most recent change of -$5.19 million (-20.47%) on September 30, 2025.
  • Over the past year, ELVN quarterly total expenses has dropped by -$3.01 million (-12.99%).
  • ELVN quarterly total expenses is now -29.41% below its all-time high of $28.54 million, reached on March 31, 2025.

Performance

ELVN Quarterly Total Expenses Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherELVNincome statement metrics

Total Expenses Formula

Total Expenses = Cost of Goods Sold + Operating Expenses + Non Operating Expenses

ELVN Total Expenses Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterly
1Y1 Year+24.4%-13.0%
3Y3 Years+259.8%+90.9%
5Y5 Years+279.4%+62.2%

ELVN Total Expenses Highs & Lows

PeriodPeriodAnnual vs HighAnnual vs HighAnnual vs LowAnnual vs LowQuarter. vs HighQuarter. vs HighQuarter. vs LowQuarter. vs Low
3Y3-Yearat high+6082.8%-29.4%+162.6%
5Y5-Yearat high+6082.8%-29.4%+162.6%
All-TimeAll-Timeat high+6082.8%-29.4%+162.6%

ELVN Total Expenses History

DateAnnualQuarterly
Sep 2025
-
$20.15M(-20.5%)
Jun 2025
-
$25.34M(-11.2%)
Mar 2025
-
$28.54M(+23.1%)
Dec 2024
$89.02M(+24.4%)
$23.18M(+0.1%)
Sep 2024
-
$23.16M(+16.1%)
Jun 2024
-
$19.95M(-12.3%)
Mar 2024
-
$22.74M(+17.4%)
Dec 2023
$71.58M(+4910.8%)
$19.37M(-6.7%)
Sep 2023
-
$20.77M(+24.2%)
Jun 2023
-
$16.72M(+13.6%)
Mar 2023
-
$14.72M(+145.7%)
Dec 2022
-$1.49M
-$32.19M(-405.0%)
Sep 2022
-
$10.55M(+18.7%)
Jun 2022
-
$8.89M(+2.5%)
DateAnnualQuarterly
Mar 2022
-
$8.67M(-39.5%)
Dec 2021
$24.74M(-40.2%)
-
Dec 2021
-
$14.32M(+4.9%)
Sep 2021
-
$13.65M(+3.7%)
Jun 2021
-
$13.16M(+28.3%)
Mar 2021
-
$10.26M(-10.9%)
Dec 2020
$41.36M(+76.3%)
$11.52M(-7.3%)
Sep 2020
-
$12.42M(+21.7%)
Jun 2020
-
$10.20M(+41.4%)
Mar 2020
-
$7.21M(+9.0%)
Dec 2019
$23.46M(+107.0%)
-
Sep 2019
-
$6.62M
Dec 2018
$11.34M(>+9900.0%)
-
Dec 2017
$0.00
-

FAQ

  • What is Enliven Therapeutics, Inc. annual total expenses?
  • What is the all-time high annual total expenses for Enliven Therapeutics, Inc.?
  • What is Enliven Therapeutics, Inc. annual total expenses year-on-year change?
  • What is Enliven Therapeutics, Inc. quarterly total expenses?
  • What is the all-time high quarterly total expenses for Enliven Therapeutics, Inc.?
  • What is Enliven Therapeutics, Inc. quarterly total expenses year-on-year change?

What is Enliven Therapeutics, Inc. annual total expenses?

The current annual total expenses of ELVN is $89.02M

What is the all-time high annual total expenses for Enliven Therapeutics, Inc.?

Enliven Therapeutics, Inc. all-time high annual total expenses is $89.02M

What is Enliven Therapeutics, Inc. annual total expenses year-on-year change?

Over the past year, ELVN annual total expenses has changed by +$17.44M (+24.36%)

What is Enliven Therapeutics, Inc. quarterly total expenses?

The current quarterly total expenses of ELVN is $20.15M

What is the all-time high quarterly total expenses for Enliven Therapeutics, Inc.?

Enliven Therapeutics, Inc. all-time high quarterly total expenses is $28.54M

What is Enliven Therapeutics, Inc. quarterly total expenses year-on-year change?

Over the past year, ELVN quarterly total expenses has changed by -$3.01M (-12.99%)
On this page